/
RSS Feed
 David Cunningham |  Kenneth MacDonald |  Mark Pomerantz |  Jorge Garcia |
REFERENCE: N Engl J Med 2006;355:11
David Cunningham, Royal Marsden Hospital
The July 6th edition of the New England Journal of Medicine leads with an article from the Royal Marsden Hospital pointing to better survival rates among patients with gastric cancer who received perioperative chemotherapy as compared with those having surgery alone. David Cunningham tells Peter Goodwin how the study (which took 16 years from design to publication) has provided clinicians with another option for extending life in gastric cancer.
David Cunningham, Royal Marsden Hospital
The July 6th edition of the New England Journal of Medicine leads with an article from the Royal Marsden Hospital pointing to better survival rates among patients with gastric cancer who received perioperative chemotherapy as compared with those having surgery alone. David Cunningham tells Peter Goodwin how the study (which took 16 years from design to publication) has provided clinicians with another option for extending life in gastric cancer.
REFERENCE: Abstract 4570
Kenneth MacDonald, University of Utah, Salt Lake City
At the 2006 Annual Meeting of the American Society of Clinical Oncology in Atlanta Kenneth MacDonald from the University of Utah in Salt Lake City explained to Sarah Maxwell how registry data has provided guidance that salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy may yield benefits in greater numbers of patients.
Kenneth MacDonald, University of Utah, Salt Lake City
At the 2006 Annual Meeting of the American Society of Clinical Oncology in Atlanta Kenneth MacDonald from the University of Utah in Salt Lake City explained to Sarah Maxwell how registry data has provided guidance that salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy may yield benefits in greater numbers of patients.
REFERENCE: Abstract 4560
Mark Pomerantz, Dana-Farber Cancer Institute, Boston
The same prostate cancer session of ASCO also heard from Mark Pomerantz of the Dana-Farber Cancer Institute in Boston that premarin – the hormonal therapy known for its use in women – may have value for treating men with androgen-dependent prostate cancer.
Mark Pomerantz, Dana-Farber Cancer Institute, Boston
The same prostate cancer session of ASCO also heard from Mark Pomerantz of the Dana-Farber Cancer Institute in Boston that premarin – the hormonal therapy known for its use in women – may have value for treating men with androgen-dependent prostate cancer.
REFERENCE: Abstract 4564
Jorge Garcia, Cleveland Clinic
In high-risk prostate cancer, neoadjuvant therapy with thalidomide plus granulocyte macrophage colony-stimulating factor appears to be a candidate therapy to prepare some patients for radical prostatectomy by manipulating immunological factors reported Jorge Garcia from the Cleveland Clinic during the ASCO conference in Atlanta.
Jorge Garcia, Cleveland Clinic
In high-risk prostate cancer, neoadjuvant therapy with thalidomide plus granulocyte macrophage colony-stimulating factor appears to be a candidate therapy to prepare some patients for radical prostatectomy by manipulating immunological factors reported Jorge Garcia from the Cleveland Clinic during the ASCO conference in Atlanta.
[audio:https://www.audiomedica.com/podcasting/asco/06.07.15_ASCO_podcast.mp3]
